Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

With AUROPHARMA's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 1.850000
forwardPE 14.533791
debtToEquity 25.310000
earningsGrowth 0.003000
revenueGrowth 0.106000
grossMargins 0.589380
operatingMargins 0.160760
trailingEps 59.820000
forwardEps 62.290000

With a current ratio of 1.85, AUROPHARMA has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that AUROPHARMA is in a strong position to meet its immediate financial obligations without difficulty.
Aurobindo Pharma Limited's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
AUROPHARMA's low Debt-to-Equity ratio means it is not excessively reliant on debt financing. This low leverage suggests lower financial risk and stronger equity control, positioning the company in a more stable financial situation and reducing vulnerability to debt-related issues.
AUROPHARMA's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that AUROPHARMA is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

Price projections for AUROPHARMA have been gradually reduced, reflecting growing uncertainty about the company's future performance. The downward revisions indicate analysts are lowering their expectations for AUROPHARMA's market trajectory.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


The recent buy bias for AUROPHARMA from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see AUROPHARMA as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.